Compare PRTA & FPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTA | FPI |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | Ireland | United States |
| Employees | N/A | 12 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 539.9M | 503.5M |
| IPO Year | 2013 | 2013 |
| Metric | PRTA | FPI |
|---|---|---|
| Price | $11.10 | $10.81 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 1 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | ★ 388.4K | 271.7K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 3.14% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.61 |
| Revenue | $814,000.00 | ★ $52,178,000.00 |
| Revenue This Year | $1,111.38 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $18.90 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.32 | $9.37 |
| 52 Week High | $11.69 | $13.23 |
| Indicator | PRTA | FPI |
|---|---|---|
| Relative Strength Index (RSI) | 60.89 | 32.17 |
| Support Level | $9.69 | $10.77 |
| Resistance Level | $11.63 | $11.06 |
| Average True Range (ATR) | 0.39 | 0.22 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 66.19 | 6.19 |
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.